Glenn David - 09 Feb 2026 Form 4 Insider Report for PHIBRO ANIMAL HEALTH CORP (PAHC)

Reporting relationship: Chief Financial Officer
Issuer ticker: PAHC
Reported as of: 09 Feb 2026
Net transaction value: -$646,758
SEC form: 4
Accepted by SEC: 11 Feb 2026, 16:15:07 UTC
Prior SEC filing: 19 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Judith Weinstein, as Attorney-in-Fact for Glenn David

Key filing fact

Glenn David filed Form 4 for PHIBRO ANIMAL HEALTH CORP (PAHC) on 11 Feb 2026.

Key facts

This page summarizes Glenn David's Form 4 filing for PHIBRO ANIMAL HEALTH CORP (PAHC).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2026, 16:15.

Change

Previous filing in this sequence was filed on 19 Aug 2025.
Current net transaction value: -$646,758.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001606256 Primary reporting owner

David Glenn

Relationship: Chief Financial Officer
Address: 300 FRANK W. BURR BLVD., STE 21, TEANECK
Signature: /s/ Judith Weinstein, as Attorney-in-Fact for Glenn David
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PAHC transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +30,000
Change %: +86%
Price
Shares after: 64,845
Date: 09 Feb 2026
Ownership: Direct
Footnotes: F1

PAHC transaction

Class A Common Stock

Other

Transaction value: $646,758
Shares: -12,528
Change %: -19%
Price: $51.62
Shares after: 52,317
Date: 11 Feb 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PAHC transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -30,000
Change %: -11%
Price: $0.000000
Shares after: 240,000
Date: 09 Feb 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 30,000
Exercise price
Footnotes: F1, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Shares were issued in settlement of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock.

Footnote F2

Represents shares sold in a broker assisted cashless exercise program to satisfy tax withholding obligations upon the receipt of Class A Common Stock in connection with the vesting and settlement of the RSUs.

Footnote F3

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.54 to $52.03. The reporting person undertakes to provide to Phibro Animal Health Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

On February 9, 2024 (the "Grant Date"), the reporting person was granted 300,000 RSUs pursuant to the Issuer's 2008 Incentive Plan and an RSU award agreement (the "Award Agreement").

Footnote F5

Pursuant to the Award Agreement, (i) 150,000 RSUs are subject to time vesting (collectively, the "Time Vesting RSUs") and vest in equal installments on each of the first five anniversaries of the Grant Date, subject to continued service through each such vesting date, and (ii) 150,000 RSUs are subject to performance vesting (collectively, the "Performance Vesting RSUs") and vest (with linear interpolation to apply for achievement between increments) based upon achievement of the arithmetic average of the Issuer's closing stock price per share for each trading day in the 90-calendar day period ending five years from the Grant Date, from $20 to $60 and above, subject to Mr. David's continued employment on such date. Time Vesting RSUs and Performance Vesting RSUs, in each case, are subject to earlier vesting upon certain qualifying termination events.